Optimizing pharma operations in 340B and beyond | McDermott

McDermott Will & Schulte, a global law firm

VIRTUAL

Optimizing pharma operations in 340B and beyond: Investor opportunities and compliance considerations

Webinar

February 3, 2026

Event details

February 3, 2026

Webinar

This event is in the past. See recordings and other materials from this event below.

Pharmacies are taking a more active and creative role in healthcare delivery, evolving beyond routine prescription dispensers into independent healthcare stakeholders with expanded roles and tech-driven capabilities. From prior authorizations and price transparency to adherence tools and prescriber-facing portals, these prescribing-adjacent services are reshaping the market and attracting interest from investors and strategic partners.

Join McDermott for an in-depth discussion on how investors can capitalize on this transformation while mitigating regulatory risk. This program will explore:

  • Vendor arrangements and business conversions: How shifting operations in-house and strategic partnerships are changing the game, and how to do it within regulatory guardrails
  • Prescribing-adjacent services: Where consumerization meets pharma services—and how investors can capitalize on efficiencies within adherence, price transparency, medication therapy management, and more
  • 340B program dynamics: Why investors are entering this space and what risks and opportunities they need to understand
  • Risk and compliance considerations: Key diligence points around prior authorization and operational optimization
Speakers